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ABSTRACT
Antimicrobial prophylaxis using cefaclor or trimethoprim-sulfamethoxazole (co-trimoxazole) is 
recommended for children with vesicoureteral reflex (VUR) to prevent recurrent urinary tract 
infection (UTI). This retrospective study was performed by reviewing the data of children ≥5 
years of age treated for recurrent UTI in six hospitals from 2010 to 2015. The criteria for UTI 
diagnosis is fever (≥38°C) and positive results in urine culture (>104 colony-forming units/ml in 
midstream or withdrawn urine specimens). In total, 41 children were reviewed, and 31 children 
had recurrent UTI without antimicrobial prophylaxis and 10 had breakthrough (BT)-UTI treated 
with prophylaxis using cefaclor or co-trimoxazole. In the cases of BT-UTI treated with prophylaxis, 
5 children received cefaclor and 5 received co-trimoxazole. We collected data on pathogens, 
antimicrobial resistance, and antimicrobial agents chosen for the empirical treatment of recurrent 
UTI. We also evaluated the validity of empirical therapy for recurrent UTI in this study. Various 
pathogens were found in children who received prophylaxis with cefaclor. The rate of empirical 
antimicrobial agents that were inappropriate based on antimicrobial susceptibility tests was 
higher in children who received prophylaxis with cefaclor (60.0%) than in those who received no 
prophylaxis (25.9%) or prophylaxis with co-trimoxazole (20.0%). Prophylaxis with cefaclor was 
found to be a risk factor for inappropriate empirical treatment in BT-UTI cases. The results suggest 
that the choice of empirical antimicrobial agents in BT-UTI cases should be carefully considered 
before treatment with prophylaxis. To encourage the adequate use of antimicrobial agents, we 
recommend prophylaxis with co-trimoxazole to prevent recurrent UTI.
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Vesicoureteral reflex (VUR) is a common urolog-
ic anomaly, with a prevalence rate of 1%–2% in 
children11), and it increases the risk of recurrent 
urinary tract infection (UTI). Antimicrobial pro-
phylaxis is recommended for children with VUR to 
prevent recurrent UTI. Cefaclor or trimethoprim-
sulfamethoxazole (co-trimoxazole) is mainly selected 
in Japan3,12). One advantage of antimicrobial pro-
phylaxis is that it reduces the risk of recurrent 
UTI2,9,10); however, antimicrobial prophylaxis may 
be a risk factor for inducing resistant bacteria. In 
particular, cephalosporin prophylaxis was reported 
to be a risk factor for resistant bacteria in break-
through UTI (BT-UTI). The amount of extended-
spectrum β-lactamase (ESBL)-producing organisms 
was reported to be higher in children receiving 
cephalosporin1,4,5). Antimicrobial agents used for 
prophylaxis and the treatment of UTI are selected 
by the attending physician. We collected data on 
pathogens, antimicrobial resistant patterns, and 
antimicrobial agents chosen for empirical treatment 
of recurrent UTI. We hypothesized that the rates of 
pathogen resistance and inappropriate treatment 
with empirical antimicrobial agents, determined 
based on antimicrobial susceptibility tests, were 
higher with prophylaxis for VUR treatment. We 
investigated the difference in the antimicrobial re-
sistant rate for ESBL-producing bacteria in chil-
dren who received prophylaxis and in those who 
received no prophylaxis. We also evaluated the va-
lidity of empirical therapy for recurrent UTI in this 
study. Furthermore, we investigated the relation-
ship of prophylaxis with inappropriate treatment.
MATERIALS AND METHODS
This retrospective study was performed in six 
hospitals in Japan: Juntendo University Urayasu 
Hospital, Juntendo University Nerima Hospital, 
Sanikukai Hospital, Tokyo Rinkai Hospital, Toshima 
Hospital, and Koshigaya Municipal Hospital. We 
reviewed data from April 2010 to March 2015 for 
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5 received trimethoprim-sulfamethoxazole (co-tri-
moxazole) and 5 received cefaclor (Figure 1).
The Micro Scan system panel of antibiotics was 
used for susceptibility testing in each hospital 
(Beckman Coulter). The minimum inhibitory con-
centration for the antimicrobial agents was as-
sessed by microdilution according to the Clinical 
and Laboratory Standards Institute guidelines 
(M100-S19~S24). Intermediate results were con-
sidered to indicate resistance. Enterococcus faecalis 
was found to be resistant to all cephalosporins 
while Pseudomonas aeruginosa was found to be 
resistant to antimicrobials such as cefazolin and 
ceftriaxone. Inappropriate treatment was defined 
as cases in which the empirical antimicrobial agent 
used was inappropriately based on the results of an 
antimicrobial susceptibility test. The Fisher exact 
test, the Kruskal-Wallis test and Man Whitney U 
test were used for comparing the subject’s back-
grounds. We analyzed the other tables by the Fish-
er’s exact test. We considered that the p value of 
<0.05 was statistically significant, and two-side 
tests were used. Fisher’s test was carried out using 
BellCurve for Excel (Social Survey Research In-
formation Co., Ltd.). The Kruskal-Wallis test was 
carried out using Excel2016 (Microsoft Corpora-
tion).
children up to 5 years of age treated for recurrent 
UTI and requiring hospitalization. The criteria for 
UTI diagnosis is fever (≥38°C) and positive results 
in urine culture (>104 colony-forming units/ml in 
midstream or withdrawn urine specimens). Recur-
rent UTI was defined as contracting UTI, recovering 
completely, then contracting UTI again, while BT-
UTI was defined as contracting recurrent UTI after 
receiving antimicrobial agents for prophylaxis. 719 
children out of a total of 782 hospitalized cases with 
a diagnosis of UTI, were considered. 52 cases were 
recurrent UTI, and 2 cases were excluded because 
of the detection of multiple bacteria in the urine 
culture. Another case was excluded because the 
culture result showed less than 103 colony-forming 
units/ml. Additionally, 6 cases that received multiple 
antimicrobial agents for prophylaxis were excluded. 
A case that required surgery for VUR before recur-
rent UTI was also excluded. Another case wherein 
the patient was administered ampicillin for prophy-
laxis was excluded. For analyses, we retrospectively 
reviewed the data for 38 children (41 cases).
Each attending physician chose the antimicrobial 
agent for prophylaxis and treatment of recurrent 
UTI. In total, 31 cases had recurrent UTI treated 
without prophylaxis, whereas 10 had recurrent BT-
UTI treated with antimicrobial prophylaxis using 
cefaclor or co-trimoxazole. Among the BT-UTI cases, 
Figure. Children whose data were reviewed in this study
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trimoxazole had recurrent BT-UTI due to E. coli. 
A wide variety of pathogens was detected in the 
children who received prophylaxis, and this was 
particularly notable in children who received cefa-
clor.
Table 3 shows the antimicrobial agents used for 
empirical treatment. While 92.5% of children who 
did not receive prophylaxis were treated with 
cephalosporin, only 70.0% of children who received 
prophylaxis were treated with cephalosporin. The 
third generation of cephalosporin and carbapenem 
were mainly selected for empirical treatment in 
children who received cefaclor. Ampicillin and first 
or second-generation cephalosporin were mainly 
selected for empirical therapy in children who re-
ceived co-trimoxazole or no prophylaxis. 
Table 4 shows the antimicrobial susceptibility of 
co-trimoxazole and cefotaxime, isolates of ESBL-
producing bacterium, and inappropriate treatment 
rates, defined as the rate when the empirical anti-
microbial agent selected was inappropriate based 
on an antimicrobial susceptibility test. Co-trimoxa-
zole-resistant pathogens were isolated in 10 cases of 
UTI. Of these, 4 cases were of children who received 
prophylaxis, 4 were of children who received co-
trimoxazole, and 2 were of children who received 
cefaclor. Ceftriaxone-resistant pathogens were 
RESULTS
Table 1 shows the median age, gender, and VUR 
grade for each group. We defined high-grade VUR 
as grades III, IV, or V on one or both sides. The pro-
portion of children with high-grade VUR was higher 
in the group that received co-trimoxazole than in the 
group that received no prophylaxis (p = 0.0365). 
We investigated median age and rate of high-grade 
VUR children receiveing co-trimoxazole. All of the 
children with high-grade VUR received co-trimox-
azole, 60% of children received cefaclor, and 38.5% 
of children did not receive prophylaxis.
Table 2 shows the etiology of the UTI pathogen in 
each group. Escherichia coli and E. faecalis were 
the most common pathogens. Additionally, 71.0% 
children who did not receive prophylaxis had recur-
rent UTI due to E. coli. Furthermore, in this group, 
the most common pathogen, with the exception of 
two isolates (Enterobacter cloacae and Haemophi-
lus influenzae), were E. coli or E. faecalis (93.6%). 
However, only 20.0% of children who received an-
timicrobial prophylaxis had recurrent UTI due to 
E. coli. The proportion of children with E. coli was 
lower in the group that received cefaclor than in the 
group that received no prophylaxis (71.0% vs 0%, 
p = 0.0053). Also, 40% of children who received co-
Table 1. Demographic and Clinical Features of Children
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who received co-trimoxazole was particularly high 
(80.0%, p = 0.0086).
ESBL-producing bacteria were isolated from 3 
cases of UTI. Of these, 2 were of children who did 
not receive prophylaxis and one was of a child who 
received cefaclor. There were no ESBL-producing 
bacteria in children who received co-trimoxazole.
The inappropriate treatment rate for children 
with prophylaxis was higher than for those who 
found in 13 cases of UTI. Of these, 8 cases were of 
children who did not receive prophylaxis, 4 were of 
those who received cefaclor, and 1 case was of a child 
who received co-trimoxazole. The ceftriaxone-re-
sistant rate in children who received prophylaxis 
was higher than that of those who did not receive 
prophylaxis (50.0% vs 29.6%) and was significantly 
higher in children who received cefaclor (80.0%, p = 
0.053). The co-trimoxazole-resistant rate in children 
Table 2. Pathogens of UTIs
Table 3. Empirical antimicrobial agents for recurrent UTI
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agents. In contrast, most pathogens observed in 
children who received co-trimoxazole were resistant 
to co-trimoxazole, but had no resistance to cephalo-
sporin. Cephalosporin-resistant pathogens, including 
ESBL-producing bacteria, should be considered 
when children receive cefaclor as prophylaxis for 
recurrent BT-UTI.
We compared the inappropriate treatment rate 
for children who received antimicrobial prophylaxis 
with that for children who did not receive prophy-
laxis. The inappropriate treatment rate was higher 
in the former group and was highest in the chil-
dren who received cefaclor. However, these children 
received broad-spectrum antimicrobial agents for 
empirical treatment.
We confirmed that the rate of E. coli was lower 
in children who received cefaclor than in those 
who received no prophylaxis. This is similar to 
past reports. We could not confirm that children 
who received cefaclor had higher rates of ceftriax-
one-resistance and inappropriate treatment than 
those who received no prophylaxis. However, the 
ceftriaxone-resistance and inappropriate treatment 
in children who received cefaclor were the worst 
among the three groups. There was a wide variety 
of pathogens in children who received cefaclor, 
particularly. We presume that the wide variety of 
pathogens played a role in the ceftriaxone-resistance 
and the inappropriate treatment rate. We did not 
evaluate many BT-UTI cases; therefore, we could 
not confirm the rates. In future, we aspire to investi-
gate more BT-UTI cases to confirm the relationship 
between prophylaxis and inappropriate treatment. 
CONCLUSION
The tendency for children who received co-tri-
moxazole and for those who received no prophylaxis 
did not receive prophylaxis (40.0% vs 25.9%). The 
inappropriate treatment rate for children who re-
ceived cefaclor was the worst among the three 
groups (60.0%).
DISCUSSION
Cephalosporin was most frequently selected as 
the empirical antimicrobial agent in recurrent UTI 
cases. The third generation of cephalosporin was 
mainly selected for children who received cefaclor 
whereas the first or second generation was mainly 
selected for children who received co-trimoxazole or 
no prophylaxis. For BT-UTI cases, we speculated 
that each attending physician selected a broad-
spectrum agent for empirical treatment because 
the number of resistant pathogens is higher in BT-
UTI with prophylaxis. This tendency was observed 
among children who received cefaclor more often 
than in those who received co-trimoxazole. Past 
studies reported that resistant bacteria are higher 
when BT-UTI is treated with prophylaxis. Prophy-
laxis with cephalosporin was reported to have the 
highest risk of inducing resistant bacteria, includ-
ing ESBL-producing bacteria. In this study, we 
compared children who received co-trimoxazole 
with those who received cefaclor and found similar 
results. Increasing ESBL-producing bacteria have 
been reported7,8). Even in the Japanese pediatric 
field, ESBL-producing bacteria have been detected 
and are considered an important problem6). A nor-
mal neonate that was an ESBL-producing bacteria 
carrier was reported recently13). The risk factor of 
increasing resistant bacterium should be dissemi-
nated to prevent the spread of infection. Various 
pathogens were found in children with BT-UTI 
who received cefaclor, and most of these bacteria 
were resistant to a large number of antimicrobial 
Table 4. Frequency of Resistance to Antibiotics
44 T. Nomura et al
L.A. 2005. Antibiotic Resistance patterns in Chil-
dren Hospitalized for urinary tract infections. Arch. 
pediatr. adolesc. Med. 159: 924-928.
6. Minami, K., Shoji, Y., Kasai, M., Ogino, Y., Nakamura, 
T., Kawakami, Y., et al. 2012. Proportion of rectal 
carriage of extended-spectrum β-lactamase-producing 
Enterobacteriaceae in the inpatients of a pediatric 
tertiary care hospital in Japan. Jpn. J. Infect. Dis. 
65(6): 548-550.
7. Paterson, D.L. and Bonomo, R.A. 2005. Extended-
Spectrum β-Lactamases: a Clinical Update. Clin. 
Microbiol. Rev. 18: 657-686.
8. Pitout, J.D. and Laupland, K.B. 2008. Extended-
spectrum β-lactamase-producing Enterobacteriaceae: 
an emerging public-health concern. Lancet Infect. 
Dis. 8: 159-166.
9. RIVUR Trial Investigators., Hoberman, A., 
Greenfield, S.P., Mattoo, T.K., Keren, R., 
Mathews, R., et al. 2014. Antimicrobial prophylaxis 
for children with vesicular reflux. N. engl. j. med. 
370: 2367-2376.
10. Roussey-Kesler, G., Gadjos, V., Idres, N., Horen, 
B., Ichay, L., Leclair, M.D., et al. 2008. Antibiotic 
prophylaxis for the prevention of recurrent urinary 
tract infection in children with low grade vesicoure-
teral reflux: results from a prospective randomized 
study. J. urol. 179: 674-679.
11. Sargent, M.A. 2000. What is the normal prevalence 
of vesicoureteral reflux? Pediatr. Radiol. 30: 587-
593.
12. Subcommittee on Urinary Tract Infection, Steering 
Committee on Quality Improvement and Management. 
and Roberts, K.B. 2011. Urinary Tract Infection: 
Clinical Practice Guideline for the Diagnosis and 
Management of the Initial UTI in Febrile Infants 
and Children 2 to 24 Months. Pediatrics 128(3): 
595-610.
13. Watanabe, T., Matsuda, T., Kinjyoi, K., Masunaga, 
Y., Hirano, K., Uemura, N., et al. 2015. A clinical 
features about infection caused by bacterias produc-
ing extended-spectrum beta-lactamase. Japanese 
Journal of Pediatrics 68: 1874-1878. (in Japanese)
was observed to be the same in this study. However, 
in children who received cefaclor, the inappropriate 
treatment rate was the worst among the three 
groups along with the presence of a wide variety of 
pathogens. Nevertheless, these children received 
broad-spectrum antimicrobial agents for empirical 
treatment. Prophylaxis with cefaclor seems to be a 
risk factor for inappropriate empiric treatment in 
BT-UTI cases. The results of this study suggest 
that the choice of empirical antimicrobial agent in 
BT-UTI cases should be considered carefully. To 
facilitate adequate antimicrobial agent usage, we 
recommend prophylaxis with co-trimoxazole to 
prevent recurrent UTI. 
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